PTC Therapeutics, Inc. (PTCT)

44.17 -2.50 (-5.36%) At close: 04:00PM EDT

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,167

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Stuart W. Peltz Ph.D.	Co-Founder, CEO & Exec. Director	1.64M	N/A	1960
Dr. Allan Steven Jacobson Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Independent Director	142.5k	N/A	1946
Ms. Emily Luisa Hill	Chief Financial Officer	814.34k	1.2M	1980
Dr. Neil Almstead Ph.D.	Chief Technical Operations Officer	810.82k	4.12M	1967
Mr. Mark Elliott Boulding	Exec. VP & Chief Legal Officer	824.09k	355.34k	1961
Mr. Eric Pauwels	Chief Bus. Officer	810.47k	N/A	1961
Ms. Dawn A. Svoronos	Advisor	62k	N/A	1953
Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS	Chief Operating Officer	N/A	N/A	1972
Ms. Christine Utter	Sr. VP, Chief Accounting Officer & Head of People Services	N/A	N/A	1978
Ms. Ellen Welch Ph.D.	Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Corporate governance

PTC Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2023 is 5. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.